surmount-4 tirzepatide withdrawal weight regain after the of (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the trial indicated. Read more at: https://www.medpagetoday.com/endocrinology/obesity November Blog - What happens
Description
Wegovy has a cardiovascular risk-reduction indication for certain adults with established cardiovascular disease and overweight or obesity
7 A major challenge in the management of obesity is the prevention of a return to pathologically high levels of weight and adiposity after initial success in weight loss and body re-composition
They will not cause an air embolism
Serious problems are rare, but avoiding them avoids bigger issues
